A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1

Conditions

Brain and Nervous System

Phase III

Volunteers
Health Professionals

What is the purpose of this trial?

This study will be conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 3 study. Approximately 300 subjects with newly diagnosed glioblastoma who meet all eligibility criteria will be enrolled.

Find out more about who can participate in this trial

Trial with
Denovo Biopharma LLC
Start Date
06/06/2022
End Date
06/01/2025

For more information about this study, contact:

Christina Wiess

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Antonio Omuro, MD
Professor of Neurology; Chief, Neuro-Oncology; Clinical Trials Director, Chenevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center

Sub-Investigators

Last Updated
06/07/2022
Study HIC
#2000029377

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information